US and Norwegian trials compare treatment options for opioid dependence

December 6, 2017

The current opioid epidemic is destroying lives, families, and communities. Medication is widely considered to be the most effective treatment, but far too few people who could benefit are actually treated.

Two medications, and naltrexone—representing pharmacologically and conceptually opposite approaches—are available for office-based , yet until now, patients, families, and providers have had no data to help guide their choice of treatment. New and consistent findings from two studies comparing these approaches will help.

Buprenorphine is a partial opioid agonist; it partially activates involved in pain relief and reward, and can block some of the effects of other opioids such as heroin. Treatment with buprenorphine can be started while a patient is still dependent on opioids, but patients taking buprenorphine remain opioid dependent and will experience when it is discontinued. Buprenorphine can be abused or diverted and, in the US, can only be prescribed by providers with special waivers.

Naltrexone, in contrast, is a full ; it has no stimulating effects of its own, but blocks the effects of other opioids such as heroin. Because it blocks opioid receptors, naltrexone treatment cannot be initiated until a patient is fully detoxified, as it will precipitate sudden withdrawal symptoms. Patients using naltrexone are not opioid dependent and will not experience withdrawal when it is discontinued. Naltrexone is not abused or diverted and can be prescribed by any provider.

Dr. John Rotrosen at New York University School of Medicine and Dr. Lars Tanum at the University of Oslo and Akershus University Hospital in Norway each led trials that enrolled participants from community detoxification units and randomly assigned them to naltrexone or buprenorphine. The US study involved 570 participants treated for up to 24 weeks; the Norwegian study included 159 participants treated for up to 12 weeks.

The results indicate that once started, buprenorphine (a daily sublingual film) and naltrexone (a monthly extended-release injection) are equally effective in preventing relapse, retaining patients in treatment, and reducing illicit use. Other than mild to moderate injection site reactions with naltrexone, adverse events including fatal and non-fatal overdoses were similar.

For patients who are actively using opioids, naltrexone is more difficult to initiate as many patients quit detox programs before completion. In the US study this "detox hurdle" precluded approximately one in four patients randomly assigned to naltrexone from starting treatment. The Norwegian study enrolled only after they had completed detoxification so there was no "detox hurdle."

The researchers say more work is needed to overcome the detox hurdle and facilitate a smooth transition from active use of illicit opioids to , and to improve treatment retention for both medications. In the interim, the consistent findings from these two trials should help people choose—on the basis of their lifestyle, goals and preferences—between these two-distinct office-based therapies.

Explore further: Introduction is different, but top medications for opioid addiction equally effective

Related Stories

Introduction is different, but top medications for opioid addiction equally effective

November 14, 2017
With opioid addiction officially declared a public health emergency in the U.S., medical intervention to treat the illness is increasingly important in responding to the epidemic. Now, a new study concludes that two of the ...

Extended-release naltrexone promising for opioid dependence

October 19, 2017
(HealthDay)—Extended-release naltrexone is noninferior to buprenorphine-naloxone for maintaining short-term abstinence from heroin and other illicit substances, according to a study published online Oct. 18 in JAMA Psychiatry.

Clinical trial looks at tramadol for opioid withdrawal

July 12, 2017
A randomized clinical trial published by JAMA Psychiatry compared tramadol extended-release with clonidine and buprenorphine for the management of opioid withdrawal symptoms in patients with opioid use disorder in a residential ...

FDA approves once-monthly injection for opioid addiction

December 4, 2017
(HealthDay)—Sublocade, a once-monthly injection of buprenorphine to treat opioid use disorder, has been approved by the U.S. Food and Drug Administration.

Longer detox might work better for prescription pain med addiction

October 23, 2013
(HealthDay)—A longer period of detoxification may be more effective for people being treated for addiction to prescription painkillers called opioids, according to a small new study.

Long-acting treatment for opioid addiction reduced risk of relapse

March 30, 2016
In a multicenter, randomized clinical trial, ex-prisoners who received six monthly injections of naltrexone—a long-acting medication that blocks opioid receptors in the brain—were significantly less likely to resume opioid ...

Recommended for you

Drug for spinal muscular atrophy prompts ethical dilemmas, bioethicists say

December 11, 2017
When the Food and Drug Administration approved the first drug for people with spinal muscular atrophy a year ago, clinicians finally had hope for improving the lives of patients with the rare debilitating muscular disease. ...

FDA's program to speed up drug approval shaved nearly a year off the process

December 7, 2017
Speeding the pace at which potentially lifesaving drugs are brought to market was a rallying cry for Donald Trump as a candidate, and is a stated priority of his Food and Drug Administration commissioner, Dr. Scott Gottlieb. ...

Dangers of commonly prescribed painkillers highlighted in study

December 6, 2017
Commonly prescribed painkillers need to be given for shorter periods of time to reduce the risk of obesity and sleep deprivation, a new study has revealed.

Viagra goes generic: Pfizer to launch own little white pill

December 6, 2017
The little blue pill that's helped millions of men in the bedroom is turning white. Drugmaker Pfizer is launching its own cheaper generic version of Viagra rather than lose most sales when the impotence pill gets its first ...

Surgery-related opioid doses can drop dramatically without affecting patients' pain

December 6, 2017
Some surgeons might be able to prescribe a third of opioid painkiller pills that they currently give patients, and not affect their level of post-surgery pain control, a new study suggests.

Four-fold jump in deaths in opioid-driven hospitalizations

December 4, 2017
People who end up in the hospital due to an opioid-related condition are four times more likely to die now than they were in 2000, according to research led by Harvard Medical School and published in the December issue of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.